DaVita HealthCare Partners Inc. (DVA) Shares Down 4.9%
DaVita HealthCare Partners Inc. (NYSE:DVA)’s share price was down 4.9% during mid-day trading on Friday . The stock traded as low as $62.76 and last traded at $64.32, with a volume of 3,771,037 shares changing hands. The stock had previously closed at $67.65.
Several equities analysts recently issued reports on DVA shares. TheStreet cut DaVita HealthCare Partners from a “buy” rating to a “hold” rating in a report on Monday, August 8th. Zacks Investment Research cut DaVita HealthCare Partners from a “hold” rating to a “sell” rating in a report on Monday, July 18th. Wells Fargo & Co. reiterated a “buy” rating on shares of DaVita HealthCare Partners in a report on Saturday, June 4th. Robert W. Baird reiterated a “buy” rating on shares of DaVita HealthCare Partners in a report on Sunday, May 8th. Finally, JPMorgan Chase & Co. raised their price target on DaVita HealthCare Partners from $74.00 to $75.00 and gave the company a “neutral” rating in a report on Tuesday, August 9th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and five have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $78.00.
The firm has a market cap of $13.34 billion and a P/E ratio of 37.51. The company has a 50 day moving average price of $75.00 and a 200-day moving average price of $73.18.
DaVita HealthCare Partners (NYSE:DVA) last announced its quarterly earnings data on Monday, August 8th. The company reported $1.01 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.98 by $0.03. During the same period last year, the business posted $0.95 earnings per share. The company had revenue of $3.72 billion for the quarter, compared to the consensus estimate of $3.67 billion. The firm’s quarterly revenue was up 8.2% compared to the same quarter last year. On average, equities research analysts forecast that DaVita HealthCare Partners Inc. will post $3.78 EPS for the current year.
In related news, CFO James K. Hilger sold 3,416 shares of the firm’s stock in a transaction dated Monday, May 23rd. The stock was sold at an average price of $76.79, for a total value of $262,314.64. Following the sale, the chief financial officer now directly owns 29,147 shares of the company’s stock, valued at $2,238,198.13. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Pamela M. Arway sold 10,824 shares of the firm’s stock in a transaction dated Wednesday, May 25th. The stock was sold at an average price of $77.16, for a total value of $835,179.84. Following the completion of the sale, the director now directly owns 36,394 shares in the company, valued at $2,808,161.04. The disclosure for this sale can be found here.
Several hedge funds have bought and sold shares of DVA. Dimensional Fund Advisors LP boosted its stake in DaVita HealthCare Partners by 18.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,203,299 shares of the company’s stock valued at $83,884,000 after buying an additional 191,255 shares during the last quarter. BlackRock Advisors LLC boosted its stake in DaVita HealthCare Partners by 34.8% in the fourth quarter. BlackRock Advisors LLC now owns 754,037 shares of the company’s stock valued at $52,564,000 after buying an additional 194,863 shares during the last quarter. Jennison Associates LLC boosted its stake in DaVita HealthCare Partners by 0.5% in the fourth quarter. Jennison Associates LLC now owns 440,195 shares of the company’s stock valued at $30,686,000 after buying an additional 2,084 shares during the last quarter. KBC Group NV boosted its stake in DaVita HealthCare Partners by 82.7% in the fourth quarter. KBC Group NV now owns 35,965 shares of the company’s stock valued at $2,507,000 after buying an additional 16,281 shares during the last quarter. Finally, Bridgewater Associates LP purchased a new stake in DaVita HealthCare Partners during the fourth quarter valued at $2,227,000.
DaVita HealthCare Partners Inc is a provider of kidney care services. The Company operates Kidney Care division and HealthCare Partners (HCP) division. Its segments include U.S. dialysis and related lab services, HCP and Other-Ancillary services and strategic initiatives. Its Kidney Care division is a provider of dialysis services in the United States, treating patients with chronic kidney failure and end stage renal disease (ESRD).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.